Injectable glucagon-like peptide-1 receptor agonist therapies (GLP-1 RAs) are an effective and established modern treatment option for patients with obesity or type 2 diabetes mellitus (T2DM) [1, 2]. This evidence concerns the gene GLP1R and obesity disorder.